Get started

Financials · PETS

PetMed Express Inc. (PETS) financials

For the twelve months ended Jun 30, 2026, PetMed Express Inc. reported $168.86M of revenue and -$29.28M of net income.

Revenue, TTM
$168.86M
Revenue growth, YoY
-20.3%
Net income, TTM
-$29.28M
Net margin
-17.3%
Free cash flow, TTM
-$27.82M
EPS, diluted, TTM
-$1.37
Cash
$13.08M
P/S
0.16
Market cap
$26.4M
Annual revenue$179.02M
FY2017FY2026
Annual net income-$57.29M
FY2017FY2026
Annual free cash flow-$33.01M
FY2017FY2026

PETS revenue and earnings growth

PETS revenueQ1 2027$41.02M

Quarter YoY
-19.9%
QoQ
-4.2%
FY YoY
-21.1%
5Y CAGR
-10.0%
10Y CAGR
-2.7%

PETS revenue was $41.02M in fiscal Q1 2027 (ended Jun 30, 2026), down 19.9% from a year earlier and down 4.2% from the prior quarter. For the full fiscal 2026 it was $179.02M, down 21.1% from fiscal 2025. Compound annual growth was -10.0% over 5 years and -2.7% over 10 years. It rose in 6 of the last 10 fiscal years.

PETS net incomeQ1 2027-$6.14M

PETS net income was -$6.14M in fiscal Q1 2027 (ended Jun 30, 2026), compared with -$34.15M a year earlier. For the full fiscal 2026 it was -$57.29M, compared with -$6.27M in fiscal 2025.

PETS EPSQ1 2027-$0.28

PETS diluted EPS was -$0.28 in fiscal Q1 2027 (ended Jun 30, 2026), compared with -$1.65 a year earlier. For the full fiscal 2026 it was -$2.74, compared with -$0.30 in fiscal 2025.

PETS free cash flowQ1 2027-$8.33M

PETS free cash flow was -$8.33M in fiscal Q1 2027 (ended Jun 30, 2026), compared with -$13.56M a year earlier. For the full fiscal 2026 it was -$33.01M, compared with -$395.0K in fiscal 2025.

Export CSV

Income statement

Income statement
Line item
FY2026
Mar 31, 2026
FY2025
Mar 31, 2025
FY2024
Mar 31, 2024
FY2023
Mar 31, 2023
FY2022
Mar 31, 2022
FY2021
Mar 31, 2021
FY2020
Mar 31, 2020
FY2019
Mar 31, 2019
FY2018
Mar 31, 2018
FY2017
Mar 31, 2017
Revenue$179.02M$226.97M$274.10M$247.57M$272.28M$303.58M$284.13M$283.42M$273.80M$249.18M
Cost of revenue-$157.84M$189.33M$171.07M$195.34M$219.27M$202.88M$188.10M$175.99M$169.86M
Gross profit$50.22M$69.14M$84.77M$76.50M$76.94M$84.32M$81.25M$95.31M$97.81M$79.31M
Selling, general and admin$50.73M$38.65M$55.25M$41.71M$31.11M$29.72M$25.26M$24.77M$24.29M$22.80M
Operating income-$58.67M-$1.53M-$8.16M$6.05M$24.29M$30.53M$30.98M$46.17M$52.14M$37.48M
Pre-tax income-$57.36M-$587.0K-$6.27M$7.45M$24.18M$30.95M$33.89M$49.12M$53.79M$37.92M
Income tax-$73.0K$5.68M$1.19M$2.31M$5.47M$7.03M$8.04M$11.38M$16.51M$14.11M
Net income-$57.29M-$6.27M-$7.46M$5.14M$18.72M$23.92M$25.85M$37.74M$37.28M$23.82M
EPS, basic-$2.74-$0.30-$0.37$0.25$0.93$1.19$1.29$1.84$1.83$1.18
EPS, diluted-$2.74-$0.30-$0.37$0.25$0.92$1.19$1.29$1.84$1.82$1.17
Diluted shares20.9M20.6M20.4M20.3M20.4M20.1M20.1M20.5M20.4M20.4M

Balance sheet

Balance sheet
Line item
FY2026
Mar 31, 2026
FY2025
Mar 31, 2025
FY2024
Mar 31, 2024
FY2023
Mar 31, 2023
FY2022
Mar 31, 2022
FY2021
Mar 31, 2021
FY2020
Mar 31, 2020
FY2019
Mar 31, 2019
FY2018
Mar 31, 2018
FY2017
Mar 31, 2017
Cash and equivalents$21.41M$54.72M$55.30M$104.09M$111.08M$118.72M$103.76M$100.53M$77.94M$58.73M
Receivables$1.91M$2.32M$3.28M$1.74M$1.91M$2.59M$3.84M$2.54M$2.29M$1.81M
Inventory$13.61M$16.20M$28.56M-------
Current assets$43.56M$78.87M$93.65M$130.43M$151.00M$161.19M$129.02M$126.43M$105.23M$81.78M
Goodwill$0$26.66M$26.66M$0------
Total assets$81.19M$148.70M$169.88M$167.48M$179.70M$187.50M$155.32M$154.43M$134.84M$112.81M
Current liabilities$52.03M$62.77M$72.16M$57.51M$56.25M$44.94M$24.34M$18.63M$18.11M$18.36M
Total liabilities$52.25M$63.57M$73.15M$57.51M$56.25M$46.22M$25.31M$19.75M$19.11M$19.44M
Shareholders' equity$28.94M$85.13M$96.73M$109.97M$123.45M$124.93M$120.34M$134.68M$115.73M$93.37M

Cash flow

Cash flow
Line item
FY2026
Mar 31, 2026
FY2025
Mar 31, 2025
FY2024
Mar 31, 2024
FY2023
Mar 31, 2023
FY2022
Mar 31, 2022
FY2021
Mar 31, 2021
FY2020
Mar 31, 2020
FY2019
Mar 31, 2019
FY2018
Mar 31, 2018
FY2017
Mar 31, 2017
Operating cash flow-$28.39M$4.72M$4.32M$27.80M$18.50M$40.08M$38.84M$45.14M$37.38M$47.20M
Capital expenditures$4.62M$5.11M$4.51M$5.26M$1.75M$2.43M$2.31M$620.0K$703.0K$10.60M
Free cash flow-$33.01M-$395.0K-$194.0K$22.54M$16.75M$37.64M$36.53M$44.52M$36.68M$36.60M
Investing cash flow-$4.62M-$5.11M-$40.67M-$10.26M-$1.75M-$2.43M-$2.31M-$620.0K-$703.0K-$10.60M
Financing cash flow-$299.0K-$181.0K-$12.44M-$24.54M-$24.38M-$22.69M-$33.30M-$21.93M-$17.47M-$15.51M
Dividends paid$21.0K$181.0K$12.44M$24.54M$24.38M$22.69M$21.80M$21.93M$17.47M$15.51M
Share repurchases----$0$0$11.50M$0--
Stock-based compensation$1.36M-$6.59M$6.87M$6.62M$4.55M$3.31M$2.82M$3.10M$2.58M$1.94M
Depreciation and amortization$9.39M$7.04M$7.06M$3.55M$2.74M-----

Key ratios

Key ratios
Line item
FY2026
Mar 31, 2026
FY2025
Mar 31, 2025
FY2024
Mar 31, 2024
FY2023
Mar 31, 2023
FY2022
Mar 31, 2022
FY2021
Mar 31, 2021
FY2020
Mar 31, 2020
FY2019
Mar 31, 2019
FY2018
Mar 31, 2018
FY2017
Mar 31, 2017
Revenue growth, YoY-21.1%-17.2%10.7%-9.1%-10.3%6.8%0.2%3.5%9.9%6.2%
Net income growth, YoY----72.5%-21.8%-7.5%-31.5%1.2%56.5%15.8%
EPS growth, YoY----72.8%-22.7%-7.8%-29.9%1.1%55.6%14.7%
Gross margin28.1%30.5%30.9%30.9%28.3%27.8%28.6%33.6%35.7%31.8%
Operating margin-32.8%-0.7%-3.0%2.4%8.9%10.1%10.9%16.3%19.0%15.0%
Net margin-32.0%-2.8%-2.7%2.1%6.9%7.9%9.1%13.3%13.6%9.6%
Free cash flow margin-18.4%-0.2%-0.1%9.1%6.2%12.4%12.9%15.7%13.4%14.7%
Return on equity-197.9%-7.4%-7.7%4.7%15.2%19.1%21.5%28.0%32.2%25.5%
Return on assets-70.6%-4.2%-4.4%3.1%10.4%12.8%16.6%24.4%27.7%21.1%
Current ratio0.841.261.302.272.683.595.306.795.814.46

Source: XBRL data PetMed Express Inc. files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

PETS peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
PETS$168.86M-20.3%-$29.28M-17.3%$26.4M
CVS$420.61B+6.7%$11.07B2.6%$107.28B
GRDN$1.46B+4.9%$74.77M5.1%$2.69B
YICN¥12.56B-12.8%-CN¥66.39M-0.5%$25.5M
RDGT$132.16M+10.2%-$1.25M-0.9%$3.6M

PETS FAQ

9 questions
  • What is PETS revenue?
    PetMed Express Inc. (PETS) reported $168.86M of revenue for the twelve months ended Jun 30, 2026. That is down 20.3% from the year before. Revenue for fiscal 2026 was $179.02M.
  • Is PETS profitable?
    No. PetMed Express Inc. reported a net loss of $29.28M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does PETS have?
    PetMed Express Inc. reported $13.08M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is PETS revenue growing?
    PetMed Express Inc.'s revenue changed -21.1% in fiscal 2026, to $179.02M. Its compound annual growth rate was -10.0% over 5 years and -2.7% over 10 years.
  • What is PETS gross margin?
    PetMed Express Inc.'s gross profit was $47.15M on $168.86M of revenue for the twelve months ended Jun 30, 2026, a gross margin of 27.9%.
  • What is PETS free cash flow?
    PetMed Express Inc. generated -$27.82M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$23.81M less capital expenditures.
  • What is PETS earnings per share?
    Diluted earnings per share were -$1.37 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did PETS last report financial results?
    The latest statements here come from PetMed Express Inc.'s 10-Q filed on Aug 13, 2026, covering the period ended Jun 30, 2026.
  • Where does this PETS financial data come from?
    Quantisnow builds these statements from the structured XBRL data PetMed Express Inc. files with the SEC. It is provided for information only and is not investment advice.